Centchroman

Product Overview

Alternative Name: Saheli, Ormeloxifene, Chhaya

Development Status: Limited Market Approval

Target: Female

Mode: Non-hormonal

Delivery Type: Oral

Duration Type: Short-acting, Emergency

Description: A non-hormonal oral contraceptive available only in India. It is a selective estrogen receptor modulator (SERM). It is also used for management of abnormal uterine bleeding (AUB) and as an emergency contraceptive, in addition to use as a weekly contraceptive.

Updated date: May 30, 2018

Vertical Tabs

Product Details

Active Pharmaceutical Ingredient (API): ormeloxifene

Potential Multi-Purpose Technology (MPT): No

Regimen: weekly

Duration: one week

Dose: 30 mg

Partner: Central Drug Research Institute, India, HLL Lifecare Limited

Status

Project Phase: Post-development

Project Stage: Marketed

Began discovery in: 1977

Status Details:
Centchroman has been in use as a weekly oral contraceptive in India for nearly 20 years.

Clinical research activities underway to develop this product for management of osteoporosis and advanced breast cancer.

Programmatic Considerations

Considerations:
Studies have shown usage can have a beneficial effect on dysfunctional uterine bleeding, endometriosis, and management of menorrhagia. May offer additional health benefits such as prevention of osteoporosis.

Additional Information

Additional Information:
Singh MM. (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 21(4): 302-47.

Download Product Report

Alternative Name: Saheli, Ormeloxifene, Chhaya

Development Status: Limited Market Approval

Target: Female

Mode: Non-hormonal

Delivery Type: Oral

Duration Type: Short-acting, Emergency

Description: A non-hormonal oral contraceptive available only in India. It is a selective estrogen receptor modulator (SERM). It is also used for management of abnormal uterine bleeding (AUB) and as an emergency contraceptive, in addition to use as a weekly contraceptive.

Updated date: May 30, 2018

Vertical Tabs

Active Pharmaceutical Ingredient (API): ormeloxifene

Potential Multi-Purpose Technology (MPT): No

Regimen: weekly

Duration: one week

Dose: 30 mg

Partner: Central Drug Research Institute, India, HLL Lifecare Limited

Project Phase: Post-development

Project Stage: Marketed

Began discovery in: 1977

Status Details: Centchroman has been in use as a weekly oral contraceptive in India for nearly 20 years. Clinical research activities underway to develop this product for management of osteoporosis and advanced breast cancer.

Considerations: Studies have shown usage can have a beneficial effect on dysfunctional uterine bleeding, endometriosis, and management of menorrhagia. May offer additional health benefits such as prevention of osteoporosis.

Additional Information: Singh MM. (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 21(4): 302-47.

Status Details:
Centchroman has been in use as a weekly oral contraceptive in India for nearly 20 years.

Clinical research activities underway to develop this product for management of osteoporosis and advanced breast cancer.

Considerations:
Studies have shown usage can have a beneficial effect on dysfunctional uterine bleeding, endometriosis, and management of menorrhagia. May offer additional health benefits such as prevention of osteoporosis.

Additional Information:
Singh MM. (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 21(4): 302-47.